Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis

PHASE3Enrolling by invitationINTERVENTIONAL

Enrollment

615

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

April 20, 2026

Study Completion Date

December 31, 2026

Conditions

Rheumatoid Arthritis (RA)Anti IL-6R

Interventions

BIOLOGICAL

Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection

"The drug was administered once every 4 weeks.~Other Names:~Tocilizumab Injection placebo control"

Trial Locations (1)

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Beijing VDJBio Co., LTD.

INDUSTRY